DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer

This study is testing a new drug called DT2216 combined with paclitaxel (a standard chemotherapy) for women with ovarian, fallopian tube, or peritoneal cancer that has come back or stopped responding to platinum-based chemotherapy. **You may be eligible if...** - You have a confirmed diagnosis of recurrent or treatment-resistant ovarian, fallopian tube, or peritoneal cancer - Your cancer can be measured on a scan (at least one lesion of a specific size) - You have adequate organ function to tolerate treatment **You may NOT be eligible if...** - Your cancer has not previously been treated with platinum-based chemotherapy - You have significant heart, kidney, or liver problems - You are pregnant or breastfeeding - You have had certain recent surgeries or other investigational treatments Talk to your doctor to see if this trial is right for you.